Differential Effects of TcdB1 and TcdB2 in C. difficile disease

TcdB1 和 TcdB2 在艰难梭菌疾病中的不同作用

基本信息

项目摘要

ABSTRACT The most recent reports indicate Clostridioides difficile is the cause of over 400,000 cases of gastrointestinal illness and nearly 30,000 deaths annually. A major factor in the virulence of C. difficile is TcdB, an intracellular bacterial toxin that glucosylates small GTPases in targeted cells. Our studies focus on determining the critical differences in TcdB1 and TcdB2, the two major variants of TcdB. TcdB1 is produced by historical strains of C. difficile and TcdB2 is produced by hypervirulent/epidemic strains of C. difficile. Understanding how these two forms of TcdB, which share 92% identity, differ in critical steps in intoxication and immunogenicity provides insight into underlying differences in virulence between historical and epidemic strains of C. difficile. Several studies, including many from our group, have found that TcdB1 and TcdB2 differ in their interactions with target cells, tropism, cytotoxicity, and immunogenicity. The objective of our work is to identify and characterize the underlying molecular and cellular details of the factors accounting for these differences in TcdB1 and TcdB2 activity. To continue this line of investigation, three specific aims to i) Determine the underlying differences in the molecular mechanism of TcdB1 and TcdB2 receptor binding and cell penetration, ii) Determine if TcdB2 subverts antigen presentation and limits humoral immunity to co-administered vaccine antigen TcdB2Δ1769-1787, and iii) Construct and test strains of C. difficile expressing mutants of TcdB1 and TcdB2 will be pursued. These studies will provide further insight into the differences in TcdB1 and TcdB2, determine the contribution of TcdB to ineffective immune memory leading to relapse, and test hypotheses related to specific TcdB functional activities in the context of C. difficile infection. Overall, the findings from this work will enhance our understanding of C. difficile disease at multiple levels and provide information needed to prevent and treat this serious human illness.
摘要 最新报告表明,艰难梭状芽胞杆菌是40多万例肺炎的病因。 每年有近30,000人死于胃肠道疾病。致病性的主要因素是C。 艰难梭菌是TcdB,一种细胞内的细菌毒素,它能使靶细胞中的小GTP酶糖基化。 我们的研究集中在确定TcdB1和TcdB2这两个主要的 Tcdb的变体。TcdB1是由艰难梭菌的历史菌株产生的,TcdB2是由 艰难梭菌的超强毒力/流行菌株。了解这两种形式的Tcdb是如何 92%的同一性,在中毒和免疫原性的关键步骤上的不同提供了洞察 艰难梭菌历史菌株和流行菌株之间毒力的潜在差异。几个 包括我们小组的许多研究发现,TcdB1和TcdB2在他们的 与靶细胞的相互作用、趋向性、细胞毒性和免疫原性。我们的工作目标是 就是识别和表征这些因子的潜在分子和细胞细节 解释了TcdB1和TcdB2活性的这些差异。要继续这条线 调查,三个具体目标:i)确定分子中潜在的差异 TcdB1和TcdB2受体结合和细胞穿透的机制,II)决定TcdB2是否 颠覆抗原递呈,限制对联合接种疫苗抗原的体液免疫 TcdB2Δ1769-1787;III)艰难梭菌表达TcdB1突变株的构建和检测 和TcdB2将被追查。这些研究将进一步深入了解TcdB1的差异 和TcdB2,确定TcdB对导致复发的无效免疫记忆的贡献, 并在艰难梭菌的背景下测试与特定TcdB功能活动有关的假设 感染。总体而言,这项工作的发现将加强我们对艰难梭菌病的了解 并提供预防和治疗这一严重人类疾病所需的信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jimmy D. Ballard其他文献

A toxin contest
一场毒素竞赛
  • DOI:
    10.1038/467665a
  • 发表时间:
    2010-10-06
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Jimmy D. Ballard
  • 通讯作者:
    Jimmy D. Ballard
CSPG4-dependent cytotoxicity for emC. difficile/em TcdB is influenced by extracellular calcium and chondroitin sulfate
艰难梭菌 TcdB 对 emC 的 CSPG4 依赖性细胞毒性受细胞外钙和硫酸软骨素的影响
  • DOI:
    10.1128/msphere.00094-24
  • 发表时间:
    2024-03-12
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    D. Annie Doyle;Paul L. DeAngelis;Jimmy D. Ballard;Sarah E. F. D'Orazio
  • 通讯作者:
    Sarah E. F. D'Orazio
Critical intermediate steps in <em>Clostridium sordellii</em> lethal toxin-induced apoptosis
  • DOI:
    10.1016/j.bbrc.2007.09.073
  • 发表时间:
    2007-11-30
  • 期刊:
  • 影响因子:
  • 作者:
    Daniel E. Voth;Jimmy D. Ballard
  • 通讯作者:
    Jimmy D. Ballard
A toxin contest
一场毒素竞赛
  • DOI:
    10.1038/467665a
  • 发表时间:
    2010-10-06
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Jimmy D. Ballard
  • 通讯作者:
    Jimmy D. Ballard

Jimmy D. Ballard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jimmy D. Ballard', 18)}}的其他基金

Oklahoma C. difficile U19 Challenge Core
俄克拉荷马州艰难梭菌 U19 挑战核心
  • 批准号:
    10625174
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
Enhancing C. difficile vaccination in the context of TcdB-mediated immunosuppression.
在 TcdB 介导的免疫抑制背景下加强艰难梭菌疫苗接种。
  • 批准号:
    10625175
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
Oklahoma CMP&I Administrative Core
俄克拉荷马州 CMP
  • 批准号:
    10554352
  • 财政年份:
    2020
  • 资助金额:
    $ 43.23万
  • 项目类别:
Oklahoma Center for Microbial Pathogenesis and Immunity
俄克拉荷马州微生物发病机制和免疫中心
  • 批准号:
    10341201
  • 财政年份:
    2020
  • 资助金额:
    $ 43.23万
  • 项目类别:
Oklahoma Center for Microbial Pathogenesis and Immunity
俄克拉荷马州微生物发病机制和免疫中心
  • 批准号:
    10554351
  • 财政年份:
    2020
  • 资助金额:
    $ 43.23万
  • 项目类别:
Oklahoma CMP&I Administrative Core
俄克拉荷马州 CMP
  • 批准号:
    10341202
  • 财政年份:
    2020
  • 资助金额:
    $ 43.23万
  • 项目类别:
Differential Effects of TcdB1 and TcdB2 in C. difficile disease
TcdB1 和 TcdB2 在艰难梭菌疾病中的不同作用
  • 批准号:
    8945312
  • 财政年份:
    2015
  • 资助金额:
    $ 43.23万
  • 项目类别:
Differential Effects of TcdB1 and TcdB2 in C. difficile disease
TcdB1 和 TcdB2 在艰难梭菌疾病中的不同作用
  • 批准号:
    10331732
  • 财政年份:
    2015
  • 资助金额:
    $ 43.23万
  • 项目类别:
Differential Effects of TcdB1 and TcdB2 in C. difficile disease
TcdB1 和 TcdB2 在艰难梭菌疾病中的不同作用
  • 批准号:
    10548849
  • 财政年份:
    2015
  • 资助金额:
    $ 43.23万
  • 项目类别:
Edema Toxin Suppression of Immune Responses During Anthrax Disease
炭疽病期间水肿毒素抑制免疫反应
  • 批准号:
    7695606
  • 财政年份:
    2009
  • 资助金额:
    $ 43.23万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了